Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28189820 | 0.75 | MKNK2 (0.42) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL20520353 | 0.72 | MKNK2 (0.42) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL4734481 | 0.72 | MKNK2 (0.37) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL3697841 | 0.71 | MKNK2 (0.49) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL4542537 | 0.70 | POLB (0.54) | MKNK2FDPSLTA4H | |
| SCHEMBL793846 | 0.69 | MKNK2 (0.48) | MKNK2FDPSLTA4HHDAC1HDAC6 | |
| SCHEMBL27474268 | 0.69 | MKNK2 (0.40) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL29229251 | 0.68 | MKNK2 (0.39) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL28839763 | 0.67 | MKNK2 (0.43) | MKNK2FDPSIRAK4LTA4HHDAC1 | |
| SCHEMBL680855 | 0.67 | FGFR1 (0.56) | MKNK2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761984-B | Method for synthesizing chiral five-membered carbocyclic purine nucleoside by asymmetric hydrogen transfer | 河南师范大学 | 2020-07-07 | — | — | CN | claimed |
| CN-109761984-A | The method of asymmetric five yuan of carbocyclic purine nucleosides of hydrogen migration synthesis of chiral | 河南师范大学 | 2019-05-17 | — | — | CN | claimed |
| CN-109761984-B | Method for synthesizing chiral five-membered carbocyclic purine nucleoside by asymmetric hydrogen transfer | 河南师范大学 | 2020-07-07 | — | — | CN | disclosed |
| CN-109761984-A | The method of asymmetric five yuan of carbocyclic purine nucleosides of hydrogen migration synthesis of chiral | 河南师范大学 | 2019-05-17 | — | — | CN | disclosed |
| CN-109761984-A | The method of asymmetric five yuan of carbocyclic purine nucleosides of hydrogen migration synthesis of chiral | 河南师范大学 | 2019-05-17 | — | — | CN | disclosed |
| EP-2564871-B1 | Therapeutic Agent for Migraine | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | disclosed |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| WO-2003011864-A1 | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002040631-A2 | DIPEPTIDE SERYL-HISTIDINE AND RELATED OLIGOPEPTIDES CLEAVE DNA, PROTEIN, AND A CARBOXYL ESTER | OHIO UNIVERSITY (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1073891-A2 | METHOD OF PREDICITING RECEPTOR MODULATING ACTIVITY | Karo Bio USA, Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1002235-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | Novalon Pharmaceutical Corporation (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999054728-A2 | METHOD OF PREDICTING RECEPTOR MODULATING ACTIVITY | KARO BIO USA, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0937253-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | Novalon Pharmaceutical Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999006839-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | NOVALON PHARMACEUTICAL CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998019162-A9 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | — | 1998-07-09 | — | — | WO | disclosed |
| WO-1998019162-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | NOVALON PHARMACEUTICAL CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | MKNK2 2702/4885FDPS 2401/4885IRAK4 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.